Bivariate analysis of symptom and medication score effect sizes in grass pollen allergen immunotherapy reveals route-dependent dissociation: implications for the combined symptom and medication score.
Gabriele Di Lorenzo, Marcello Melluso
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis examined the relationship between symptom scores (SS) and medication scores (MS) in 14 randomized controlled trials of grass pollen allergen immunotherapy (AIT) involving 4850 patients. The study found that the SS-MS relationship varied significantly by delivery route, with SCIT showing a systematic dissociation (MS effect sizes exceeding SS effect sizes) and SLIT-drops exhibiting negligible SS effects. The findings challenge the validity of the combined symptom and medication score (CSMS) as a universal endpoint.
Key findings
- SLIT-tablets showed no consistent SS-MS correlation (Pearson r = 0.001, P = .999).
- For SCIT, MS effect sizes consistently exceeded SS effect sizes, with a ratio of 2.2:1 in Varney 1991.
- SLIT-drops demonstrated negligible SS effects (g SS ≈ 0) in the sensitivity analysis.
- The overall sensitivity analysis yielded r = 0.551 (P = .064).
Why it matters
Understanding the relationship between symptom and medication scores in AIT is crucial for accurately assessing treatment efficacy. This study highlights the need for separate reporting of these measures, which can influence clinical decision-making and trial design.